Biogen

BIIBNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$36.073 B

$244.03 -4.10%

Close of 6 Nov 2026

As of 6 Nov 2026, Biogen (BIIB) has a market capitalization of $36.1B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$9.89B

#414 by revenue

Earnings

$1.29B

#322 by earnings

Shares outstanding

147,820,223

Latest filing cover page

P/E ratio

27.9

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#4Argenx SeARGX$55.8B
#5Revolution MedicinesRVMD$38.5B
#6BiogenBIIB$36.1B
#7BioNTech SEBNTX$21.6B
#8ExelixisEXEL$16.8B

What if Biogen were worth as much as…

Open the what-if tool →

Gold $28.2T

$191,021.72

Per share 783× higher

Bitcoin $1.53T

$10,335.85

Per share 42.4× higher

Apple $5.02T

$33,931.64

Per share 139× higher

Or at a round number

$50.0B $100.0B $200.0B $500.0B

Where these numbers come from

Share counts and financials for Biogen are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.